Integra Lifesciences Holdings (IART) Gross Margin (2009 - 2026)
Integra Lifesciences Holdings (IART) reported Gross Margin of 55.36% for Q1 2026, up 455.0% on a YoY basis from 9.98% in Q1 2025, and up 9.02% sequentially from 50.78% in Q4 2025.
Integra Lifesciences Holdings (IART) Gross Margin (2009 - 2026) Analysis & Trends
Integra Lifesciences Holdings (IART) has 18 years of Gross Margin data on file, last reported at 55.36% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin rose 455.0% year-over-year to 55.36%; the trailing twelve-month figure through Mar 2026 stood at 51.94% (down 160.0% YoY), and the FY2025 full-year result was 50.86%, down 391.0% from the prior year.
- Gross Margin climbed to 55.36% in Q1 2026, from 50.78% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 62.83% in Q4 2022 to a low of 50.37% in Q2 2025.
- A 5-year average of 56.26% and a median of 56.07% in 2024 frame the typical range for Gross Margin.
- Across the five-year window, Gross Margin slumped 840 bps in 2023 and jumped 455 bps in 2026, its largest moves.
- Tracing IART's Gross Margin over 5 years: stood at 62.83% in 2022, then decreased by 9 bps to 57.05% in 2023, then dropped by 1 bps to 56.27% in 2024, then retreated by 10 bps to 50.78% in 2025, then gained by 9 bps to 55.36% in 2026.
- Business Quant data shows IART's Gross Margin at 55.36% in Q1 2026, 50.78% in Q4 2025, and 51.48% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 56.20% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 63.29% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 65.35% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 69.46% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 78.01% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 62.95% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 45.22% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 38.53% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Integra Lifesciences Holdings | 1.71 Bn | 1.45 Bn | 216.98 Mn | 55.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55.36% |
| Dec 31, 2025 | 50.78% |
| Sep 30, 2025 | 51.48% |
| Jun 30, 2025 | 50.37% |
| Mar 31, 2025 | 50.81% |
| Dec 31, 2024 | 56.27% |
| Sep 30, 2024 | 52.58% |
| Jun 30, 2024 | 54.02% |
| Mar 31, 2024 | 56.07% |
| Dec 31, 2023 | 57.05% |
| Sep 30, 2023 | 57.10% |
| Jun 30, 2023 | 54.30% |
| Mar 31, 2023 | 61.15% |
| Dec 31, 2022 | 62.83% |
| Sep 30, 2022 | 61.46% |
| Jun 30, 2022 | 62.70% |
| Mar 31, 2022 | 62.15% |
| Dec 31, 2021 | 61.47% |
| Sep 30, 2021 | 62.66% |
| Jun 30, 2021 | 61.21% |